Adial Pharmaceuticals
ADIL
21 hedge funds and large institutions have $359K invested in Adial Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 6 closing their positions.
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
19% less funds holding
Funds holding: 26 → 21 (-5)
48% less capital invested
Capital invested by funds: $692K → $359K (-$333K)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$30.1K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$25.6K |
| 3 |
HF
HRT Financial
New York
|
+$8.76K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$3.85K |
| 5 |
VF
Virtu Financial
New York
|
+$2.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$93K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$38.7K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$15.9K |
| 4 |
OC
Oppenheimer & Co
New York
|
-$13K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$7K |
ADIL Hedge Fund Activity: Q4 2022 in Review
21 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q4 2022, worth a combined $359K — down 48% from $692K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ADIL and 2 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $30.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $93K sold.
- 21 institutional investors held Adial Pharmaceuticals (ADIL) as of Q4 2022, down from 26 in Q3 2022.
- Funds reported $359K of Adial Pharmaceuticals stock for Q4 2022, down 48% quarter-over-quarter.
- 2 funds opened new Adial Pharmaceuticals positions in Q4 2022 and 6 closed out, a net change of -4 holders.
- The largest Adial Pharmaceuticals buyer in Q4 2022 was Renaissance Technologies, an estimated $30.1K added.
- The largest Adial Pharmaceuticals seller in Q4 2022 was Citadel Advisors, an estimated $93K sold.
Based on aggregated 13F filings for Q4 2022.